Watch for the final EC decision on TransCon CNP in Q4 2026, which would open the EU market and drive further revenue growth. Monitor YUVIWEL patient enrollment trajectory and reimbursement expansion as key indicators of commercial uptake. The company's expectation of at least EUR 600M in full-year 2026 operating cash flow provides a benchmark for cash generation sustainability.
Drugs in focus
ASND drug pipeline →lonapegsomatropin
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed (FDA approval August 2021)
- Next catalyst
- None dated
What to watchSkytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $267.07entry
- T+1 · 4d ago +3.12%α +3.48% · $275.39
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma reported Q3 2026 product revenue of EUR 366M (+89% YoY), driven by YORVIPATH (EUR 291M, +103% YoY), SKYTROFA (EUR 59M), and YUVIWEL (EUR 16M). The company achieved an operating profit of EUR 125M (34% margin) compared to EUR 11M a year ago, and net profit of EUR 74M (EUR 1.08 diluted EPS) vs a net loss of EUR 61M. The company received positive CHMP and COMP opinions for TransCon CNP in the EU, with a final EC decision expected in Q4 2026.
Key Financial Metrics
Key Facts
- Q3 2026 product revenue EUR 366M, +89% year-over-year from EUR 194M
- YORVIPATH revenue EUR 291M, +103% YoY from EUR 143M
- SKYTROFA revenue EUR 59M vs EUR 51M YoY
- YUVIWEL revenue EUR 16M (launched Q2 2026, no prior-year comparison)
- Operating profit EUR 125M (34% margin) vs EUR 11M (5% margin) in Q3 2025
- Net profit EUR 74M (EUR 1.08 diluted EPS) vs net loss EUR 61M (EUR 1.00 loss per share) in Q3 2025
- Cash and cash equivalents EUR 964M as of Sep 30, 2026, up from EUR 616M at Dec 31, 2025
- Positive CHMP and COMP opinions received for TransCon CNP in EU; final EC decision expected Q4 2026
- Approximately 340 unique YUVIWEL patient enrollments in the U.S. through Oct 31, 2026
- Year-to-date through Nov 11, 2026, repurchased 1,998,999 shares for $459M
Financial Impact
Q3 2026 product revenue EUR 366M (+89% YoY); operating profit EUR 125M (34% margin); net profit EUR 74M; cash EUR 964M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| YORVIPATH | $290.6M | +103.1% |
| SKYTROFA | $59.4M | +17.2% |
| YUVIWEL | $15.6M | Not reported |
Risk Factors
- Final EC decision on TransCon CNP marketing authorization is pending and could be delayed or negative
- YUVIWEL launch is still early-stage; patient enrollment and reimbursement may not sustain current momentum
- Royalty obligations to BioMarin (20% US, 18% EU/South Korea/Brazil) on YUVIWEL sales through May 2030 will pressure margins
- Share repurchase program reduces cash reserves; $273.4M spent post-Q3 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (ASND), Batch item 1 | 0001612042-26-000024 |
| Document: 0001612042-26-000024-index-headers.html | 0001193125-26-456989 |
| Document: 0001612042-26-000024-index.html | 0001612042-26-000024 |
| Document: 0001612042-26-000024.txt | 0001612042-26-000024 |
| 6-K Filing (ASND), Batch item 5 | 0001193125-26-456989 |
Track record
41 reports on ASND
14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Viewing Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers